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Abstract 31 
Factor H (FH)-related protein 1 (FHR-1) is one of the five human factor H-related proteins, 32 
which share sequence and structural homology with the alternative pathway complement 33 
inhibitor FH. Genetic studies on disease associations and functional analyses indicate that 34 
FHR-1 enhances complement activation by competitive inhibition of FH binding to some 35 
surfaces and immune proteins. We have recently shown that FHR-1 binds to pentraxin 3. 36 
Here, our aim was to investigate whether FHR-1 binds to another pentraxin, C-reactive 37 
protein (CRP), analyze the functional relevance of this interaction and study the role of FHR-38 
1 in complement activation and regulation. FHR-1 did not bind to native, pentameric CRP but 39 
it bound strongly to monomeric CRP via its C-terminal domains. FHR-1 at high concentration 40 
competed with FH for CRP binding, indicating possible complement de-regulation also on 41 
this ligand. FHR-1 did not inhibit regulation of solid phase C3 convertase by FH and did not 42 
inhibit terminal complement complex formation induced by zymosan. On the contrary, by 43 
binding C3b, FHR-1 allowed C3 convertase formation and thereby enhanced complement 44 
activation. FHR-1/CRP interactions increased complement activation via the classical and 45 
alternative pathways on surfaces such as the extracellular matrix and necrotic cells. 46 
Altogether, these results identify CRP as a ligand for FHR-1 and suggest that FHR-1 enhances 47 
rather than inhibits complement activation, which may explain the protective effect of FHR-1 48 
deficiency in age-related macular degeneration. 49 
 50 
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Introduction 54 
The human factor H protein family includes the major alternative pathway regulator factor H 55 
(FH), its splice variant factor H-like protein 1 (FHL-1), and five factor H-related proteins 56 
(FHRs) (1). All members of this protein family are composed exclusively of complement 57 
control protein (CCP) domains (also known as short consensus repeats, SCRs). While the 58 
function of FH is well characterized, the role of the FH-related proteins is incompletely 59 
understood (1, 2). 60 
Despite the limited information on FHR protein functions, genetic studies linked the 61 
FHR proteins to various diseases (reviewed in (1)). The five CFHR genes have arisen through 62 
segmental duplications (3, 4), and this makes the genomic region encoding the FH and the 63 
five FHRs prone to misalignments and genomic recombination events. These may result in 64 
hybrid proteins involving FH and FHR-1 or FHR-3, gene conversion events, e.g. between the 65 
exons coding for the C termini of FH and FHR-1, gene deletions affecting CFHR1, CFHR3 66 
and CFHR4, as well as in duplication of exons (reviewed in (1)). The CFH::CFHR1 and 67 
CFHR1::CFH hybrid genes are associated with atypical hemolytic uremic syndrome (aHUS) 68 
(5-7), the deletion of the CFHR1 gene predisposes to the autoimmune form of aHUS (8, 9), 69 
and a mutant FHR-1 protein with duplicated CCPs 1-2 was described as pathogenic in a 70 
patient with C3 glomerulopathy (10). These data indicate a role of FHR-1 in the regulation or 71 
modulation of complement activation. 72 
FHR-1 is the most abundant glycoprotein among the FHRs, with estimated plasma 73 
concentration of 40-100 µg/ml (11, 12). It is composed of five CCPs that are homologous to 74 
CCPs 6-7 and CCPs 18-20 of FH (13). Two FHR-1 glycoforms, FHR-1α (37 kDa) and FHR-75 
1β (43 kDa) are detected in plasma, representing differentially glycosylated proteins (11). In 76 
addition, an acidic (FHR-1*A) and a basic (FHR-1*B) isoform of the protein exist, that differ 77 
in sequence in three amino acids (14). The CCPs 3, 4 and 5 of FHR-1 have a high degree of 78 
amino acid sequence identity (95%, 100% and 97% in FHR-1*A and 100%, 100% and 97% 79 
in FHR-1*B, respectively) to the three most C-terminal domains of FH (Fig. 1). These FH 80 
domains are responsible for host surface recognition and contain an important C3b-binding 81 
site (15-19). 82 
The homology between FHR-1 and FH suggests related functions and, indeed, FHR-1 83 
binds to C3b (12, 20), although FH, having three binding sites for C3b, shows more 84 
pronounced binding. No cofactor activity and convertase decay accelerating activity were 85 
observed for FHR-1 at the C3b and C3 convertase level in line with the lack of homologous 86 
domains in FHR-1 to the complement regulatory domains of FH (11, 12). FHR-1 was 87 
described as an inhibitor of C5 convertase and formation of the terminal pathway membrane 88 
attack complex (12), but other groups could not confirm this activity (20, 21). CCP1 and 89 
CCP2 of FHR-1 display only weak similarity to the respective CCPs of FH (42% and 34% 90 
amino acid identity to CCP6 and CCP7 of FH, respectively), but are almost identical to CCPs 91 
1-2 of FHR-2 and FHR-5. These domains contain a unique dimerization motif that allows for 92 
FHR-1, FHR-2 and FHR-5 to exist as dimeric species in vivo. Moreover, dimerization is 93 
thought to increase avidity for ligands and enhance the ability of FHR-1, FHR-2 and FHR-5 94 
to compete with FH for C3b binding in vitro (21). 95 
The FH C terminus contains binding site, in addition to C3b, for heparin and mediates 96 
cell surface binding such as attachment to endothelial cells, which was also described for 97 
FHR-1 (12, 20). Moreover, these FH domains contain binding sites for the pentraxins 98 
pentraxin 3 (PTX3) and C-reactive protein (CRP) (22-24). FHR-1 binding to PTX3 was 99 
described (23) but its interaction with CRP has not yet been analyzed. 100 
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CRP is a 115-kDa acute-phase protein with a disc-like form composed of five identical 101 
subunits, which are assembled non-covalently (25). The structure is stabilized by Ca2+ in 102 
human plasma, but CRP dissociates into its monomeric subunits in the absence of calcium, at 103 
low pH or at increased temperature (25-27). CRP levels in the plasma of healthy adults are 104 
low, with a median concentration of 0.8 µg/ml, but they increase as much as a 1000-fold 105 
during acute phase reaction (28). Several ligands have been identified for CRP, including 106 
microorganisms, phosphorylcholine, complement components (e.g., C1q, FH, C4b-binding 107 
protein, ficolins), and proteins of the extracellular matrix, but the relationship between ligand 108 
binding and function is a matter of debate in most cases (25, 29). Surface-bound CRP has 109 
been shown to inhibit the alternative pathway, possibly through the interaction with FH (30, 110 
31). The FH and FHL-1 402H variants, which are strongly associated with increased risk to 111 
develop age-related macular degeneration (AMD), were shown to bind CRP less strongly 112 
compared with the 402Y variants (32, 33). This interaction – among others – is thought to be 113 
important in the pathogenesis of AMD. The common CFHR3-CFHR1 gene deletion, causing 114 
FHR-1 deficiency, is protective in AMD (34). 115 
Therefore, the aim of this study was to evaluate FHR-1 as a potential ligand for CRP 116 
and analyze the functional relevance of this interaction. We also aimed to investigate whether 117 
FHR-1, similar to FHR-4 and FHR-5 (35, 36), has a role in complement activation by 118 
supporting formation of the C3bBb convertase. 119 
 120 
Materials and Methods 121 
 122 
Proteins, antibodies and sera 123 
Recombinant human FHR-1*A (referred to as FHR-1 in the paper), FHL-1, FHR-4A and 124 
FHR-4B were generated using the pBSV-8His Baculovirus expression vector (37), expressed 125 
in Spodoptera frugiperda (Sf9) cells, and purified by nickel-affinity chromatography as 126 
described (23, 38, 39). Recombinant human FHR-5, PTX3, and biotinylated goat anti-human 127 
PTX3 antibody were obtained from R&D Systems (Wiesbaden, Germany). Recombinant 128 
human FHR-2-gst fusion protein was purchased from Abnova (Taipei, Taiwan) and FHR-3-129 
gst fusion protein was purchased from Proteintech Europe (Manchester, UK). The C-terminal 130 
fragments of FH and the FHR proteins were generated as described (21). FHR-1*A and FHR-131 
1*B were isolated from human plasma as described (23). Recombinant FH19-20 fragment 132 
with 14 different single amino acid substitutions were produced in yeast cells (40). 133 
Purified human FH, C3, C3b, factor B (FB), factor D (FD), properdin (factor P; FP) 134 
factor I (FI), C1q, C1, recombinant human CRP, goat anti-human FH antibody, goat anti-135 
human FB antibody, goat anti-human C1q antibody and goat anti-human C4 antibody were 136 
obtained from Merck Ltd. (Budapest, Hungary). mCRP was generated from recombinant CRP 137 
by urea/EDTA chelation treatment as described previously (24). The anti-FH mAbs A254 and 138 
A255, and the anti-FP mAb A235 were from Quidel (Biomedica, Budapest, Hungary). The 139 
anti-FH mAb C18 (41) was purchased from Alexis Biochemicals (Lörrach, Germany). The 140 
goat anti-CRP antibody and the anti-mCRP mAb (clone CRP-8) were from Sigma-Aldrich 141 
Ltd. (Budapest, Hungary). The anti-pCRP mAb was purchased from Antibodies-online GmbH 142 
(Aachen, Germany). Horseradish peroxidase (HRP)-conjugated goat anti-human C3 was from 143 
MP Biomedicals (Solon, OH). HRP-conjugated swine anti-rabbit immunoglobulins, rabbit 144 
anti-goat immunoglobulins and goat anti-mouse immunoglobulins were from Dako 145 
(Hamburg, Germany). 146 
Normal human plasma was collected from healthy individuals and pooled, and sera 147 
from patients with sepsis or aHUS were obtained according to protocols approved by the 148 
institutional review board of Semmelweis University of Budapest and the National Ethical 149 
Committee (Scientific and Research Ethics Committee of the Medical Research Council). 150 
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Written approvals for the diagnostic tests and research analysis were given by the patients or 151 
their parents. IgG fractions of aHUS patients with FH autoantibodies and of healthy 152 
individuals were isolated from serum or plasma using Protein G columns as described (23). 153 
FH-depleted human serum was purchased from Complement Technology (Tyler, Texas, US). 154 
 155 
Western blot 156 
To analyze binding of native FHR-1 from human plasma to CRP, microplate wells were 157 
coated with 10 µg/ml CRP or gelatin in DPBS (Lonza, Cologne, Germany). Wells were 158 
incubated with 50% v/v NHS in DPBS (with Ca2+ and Mg2+) for 1 h at 37°C. After washing, 159 
the bound proteins were eluted with non-reducing SDS-sample buffer, separated on 10% 160 
SDS-PAGE and transferred to nitrocellulose membrane. The blot was incubated with a 161 
polyclonal goat anti-FH antibody and the corresponding secondary antibody, and developed 162 
with an ECL detection kit (Merck). 163 
 164 
Microtiter plate binding assays 165 
To measure binding of CRP to FHRs at various pH, 5 µg/ml FH, FHR-1, FHR-5 and HSA 166 
were immobilized in microtiter plate wells and, after blocking with 4% BSA (w/v) in DPBS, 167 
2.5% v/v NHS or sepsis serum, or 5 µg/ml recombinant CRP, were added in DPBS (with Ca2+ 168 
and Mg2+) at pH values 7.4, 6.5 and 5.5. CRP was detected with the goat anti-human CRP 169 
antibody that recognizes both CRP forms (42) and HRP-conjugated rabbit anti-goat 170 
immunoglobulin. TMB PLUS substrate (Kem-En-Tec Diagnostics, Taastrup, Denmark) was 171 
used to visualize binding and the absorbance was measured at 450 nm. 172 
Interaction of FHRs with pCRP was measured in TBS (10 mM Tris, 140 mM NaCl, 173 
2 mM CaCl2, 1 mM MgCl2 [pH 7.4]). FH, FHR proteins and human serum albumin (HSA) as 174 
control protein were immobilized at 65 nM in microplate wells and, after blocking with 3% 175 
BSA (w/v) in TBS, incubated with up to 50 µg/ml pCRP. CRP binding was detected with the 176 
goat anti-human CRP antibody.  177 
To measure mCRP binding to FHR proteins, FHR proteins and their C-terminal 178 
fragments were immobilized in microtiter plate wells at 5 µg/ml concentration, followed by 179 
blocking with 3% BSA (w/v) in DPBS and incubation with 10 µg/ml mCRP. Binding of 180 
mCRP was detected as described above. 181 
In some assays, 5 µg/ml CRP was immobilized in microplate wells in DPBS, which 182 
results in the decay of most bound CRP into the mCRP form (42). After blocking, FHR-1, 183 
FHR-5 and FH were added in serial dilutions for 1 h at 20°C and their binding was detected 184 
using the goat anti-FH antibody. 185 
To compare binding of mCRP to FHR-1*A and FHR-1*B, the two FHR-1 variants 186 
were immobilized at 4 µg/ml in DPBS in microplate wells, and binding of increasing amounts 187 
of mCRP was measured as described above. 188 
 To analyze PTX3 binding by FH19-20 mutants, microtiter plates were coated with 4 189 
µg/ml each of the wild-type or mutant FH19-20 fragments, diluted in TBS in 25 µl, overnight 190 
at 4°C. The wells were washed after each step with TBS containing 0.05% Tween-20 (v/v). 191 
After blocking with 4% BSA (w/v) in TBS for 1 h at 20°C, 5 µg/ml PTX3 was added in TBS 192 
for 1 h at 37°C. Bound PTX3 was detected with a biotinylated goat anti-PTX3 antibody 193 
followed by HRP-conjugated streptavidin. 194 
To measure C1q binding to FHR-1-bound mCRP, microplate wells were coated with 4 195 
µg/ml recombinant FHR-1 and, as control, with gelatin, and then incubated with 5 µg/ml 196 
mCRP for 1 h at 20°C. After washing with DPBS containing 0.05% Tween-20 (v/v), C1q was 197 
added in increasing concentrations for 1 h at 20°C, and C1q binding was detected using anti-198 
C1q and the corresponding secondary antibody. Binding of C1 was similarly measured by 199 
incubating the wells with 10 µg/ml C1 instead of C1q. 200 
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 In inhibition assays, 5 µg/ml FHR-1 was immobilized in microplate wells. The mAbs 201 
C18 and A255 were added in 10 µg/ml in DPBS, and IgG fractions derived from sera of 202 
aHUS patients containing FH autoantibodies or sera of healthy individuals, were added in 500 203 
µg/ml, for 15 min at 20°C, followed by the addition of mCRP in 5 µg/ml final concentration. 204 
The binding of mCRP was detected as described above. 205 
 206 
Competition assays 207 
To measure competition between PTX3 and mCRP, immobilized FHR-1 (5 µg/ml) was 208 
incubated with 5 µg/ml PTX3 in the absence or presence of serial dilutions of mCRP in 209 
microtiter plate wells. Bound PTX3 was detected with a biotinylated goat anti-human PTX3 210 
antibody. 211 
For FH 15-20/FHR-1 inhibition assays, 10 µg/ml recombinant FH 15-20 fragment was 212 
immobilized and incubated with 5 µg/ml mCRP in the absence or presence of 1 µM FHR-1. 213 
Bound mCRP was measured with a polyclonal goat anti-human CRP antibody and the 214 
corresponding secondary antibody. Competition of FHR-1 with FHL-1 was similarly 215 
measured. 216 
 217 
C3 convertase assembly and decay accelerating activity assays 218 
To measure the effect of FHR-1 on the assembly and activity of the C3bBb alternative 219 
pathway C3 convertase, C3b was immobilized at 5 µg/ml in microplate wells. FH (10 µg/ml), 220 
FHR-1 (50 µg/ml), FHR-5 (10 µg/ml), or BSA (50 µg/ml) were added together with FB, FD 221 
and properdin to generate C3bBb convertase as described (36). The formed C3bBb was 222 
detected using polyclonal anti-FB antibody. The convertase activity was measured by adding 223 
10 µg/ml purified C3 for 1 h at 37°C and quantifying the generated C3a by a C3a ELISA kit 224 
(Quidel). Formation of the C3bBb alternative pathway C3 convertase on surface-bound FHR-225 
1 was measured as described previously (36). 226 
To investigate decay accelerating activity of FHR-1, the C3bBb convertase was built 227 
up as described (36), then FH (2.5 µg/ml), FHR-1 (10 µg/ml), FHR-5 (10 µg/ml), or FH plus 228 
FHR-1 or FH plus FHR-5 were added for 30 minutes at 20°C in DPBS. The remaining 229 
convertase was detected with a polyclonal anti-FB antibody. 230 
Cell-derived ECM was prepared by culturing the human retinal pigmented epithelial 231 
cell line ARPE-19 (ATCC, LGC Standards GmbH, Wesel, Germany) in 96-well tissue culture 232 
plates, coated with 0.2% (w/v) gelatin, in DMEM:F12 medium (Lonza) supplemented with 233 
10% FCS, penicillin (100 U/ml), streptomycin (100 μg/ml), and Amphotericin B (250 ng/ml), 234 
in a cell incubator with 5% CO2 (v/v) at 37°C. Cells were removed by incubation with DPBS 235 
containing 20 mM EDTA; removal was controlled visually by microscopy. To measure the 236 
formation of the C3bBb C3 convertase on cell-free ECM, the washed ECM was blocked with 237 
4% (w/v) BSA in DPBS containing 0.05% Tween-20 (v/v), then the wells were sequentially 238 
incubated with 5 μg/ml mCRP, 50 μg/ml FHR-1, and 50 μg/ml C3b (all in DPBS, 1 hr at 239 
20°C, with washing steps). Purified FB (2 μg/ml), FD (0.2 μg/ml) and FP (4 μg/ml) were 240 
added in convertase buffer (containing 2 mM Ni2+, 4% (w/v) BSA and 0.05% (v/v) Tween-241 
20) at 37°C for 30 min to generate the C3bBb convertase as described (36). The formed 242 
C3bBb was detected with anti-FB antibody as above.  243 
 244 
Terminal pathway inhibition assays 245 
To assess possible inhibition of the terminal pathway by FHR-1, complement activation was 246 
induced by adding 20 µg/ml zymosan to 30% NHS (v/v) in DPBS in the absence or presence 247 
of 1 µM FH, FHR-1 or FH plus FHR-1 in a final volume of 20 µl. After incubation for 30 248 
minutes at 37°C, terminal pathway activation was detected by measuring the generated C5b-9 249 
complexes with a C5b-9 ELISA kit (Quidel). 250 
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 251 
Complement activation assays 252 
To assess functional consequence of FHR-1/FH competition, 10 µg/ml CRP was immobilized 253 
in microtiter plate wells and, after blocking and washing, 20% (v/v) NHS or factor H-depleted 254 
serum was added in the absence or presence of 1 µM FHR-1 or 300 nM FHR-5, used as a 255 
control protein. After incubation for 30 minutes at 37°C, C3 deposition was detected with a 256 
HRP-labeled polyclonal anti-C3 antibody. 257 
To measure complement activation and C3 convertase formation on FHR-1, microtiter 258 
plate wells were coated with 5 µg/ml FHR-1, FHR-4B and HSA. After blocking with 4% 259 
BSA (w/v) in DPBS, wells were incubated with 10% normal human serum with or without 5 260 
mM Mg2+-EGTA or 5 mM EDTA for 30 min at 37°C. Deposition of C3b, FB and FP was 261 
detected using the corresponding primary and secondary antibodies as described (35). 262 
To measure classical pathway activation, microplate wells were coated with 4 µg/ml 263 
recombinant FHR-1 and, as control, with gelatin, and then incubated with 5 µg/ml mCRP for 264 
1 h at 20°C. After washing with DPBS containing 0.05% Tween-20 (v/v), 1% (v/v) normal 265 
human serum in DPBS containing Mg2+ and Ca2+ (Lonza), or in DPBS containing 20 mM 266 
EDTA, was added for 30 min at 37°C. C4-fragment deposition was detected using polyclonal 267 
anti-C4 antibody. To measure C4 deposition on ARPE-19 cell-derived ECM, the washed cell-268 
free ECM was sequentially incubated with 20 µg/ml recombinant FHR-1 and 5 µg/ml mCRP, 269 
then exposed to 1% human serum. C4 fragments were detected as above. 270 
 271 
Flow cytometry 272 
HUVEC were cultured in EGM-2 medium (both from Lonza) supplemented according to the 273 
manufacturer’s instructions. Confluent cell layer was removed by incubation with Trypsin-274 
EDTA solution (Lonza). Necrosis of HUVEC was induced by heat treatment (65°C, 30 min). 275 
Necrotic HUVEC (5 × 105 cells/sample) were left untreated or were preincubated with 2.5 276 
µg/ml mCRP, then incubated with 25 µg/ml recombinant FHR-1 in DPBS containing Mg2+ 277 
and Ca2+ (Lonza). After washing, cells were exposed to 5% normal human serum in buffer 278 
containing 5 mM Mg2+-EGTA. The C3bBb convertase was detected by serial incubation with 279 
anti-FB and Alexa488-labeled rabbit anti-goat Ig antibody (Invitrogen; Thermo Fisher 280 
Scientific, Waltham, MA USA). Necrotic cells were gated based on positive staining for 281 
propidium iodide. Cells were measured using a DB FACSCalibur flow cytometer (BD 282 
Biosciences, Heidelberg, Germany) and CellQuest Pro software, and data were analyzed 283 
using FCS Express 3.0 (BD Biosciences). 284 
 285 
Visualization of ligand binding sites on FH19-20 286 
Ligand binding sites on FH19-20 (Protein Data Bank accession code 2G7I) (43) were 287 
visualized using PyMOL (www.pymol.org). 288 
 289 
Statistical analysis 290 
Statistical analysis was performed using GraphPad Prism version 4.00 for Windows 291 
(GraphPad Software, San Diego California USA). A p value < 0.05 was considered 292 
statistically significant. 293 
 294 
Results 295 
Binding of the two CRP forms to the FHR proteins 296 
First, we investigated if binding of native FHR-1 to CRP can be detected from human serum. 297 
CRP was immobilized in microplate wells, which were then incubated with serum. The bound 298 
proteins were eluted and analyzed by SDS-PAGE and Western blotting using polyclonal anti-299 
FH, which detects both FH and FHR-1. This experiment revealed prominent binding of FH 300 
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and both FHR-1 glycoforms to CRP (Fig. 2A). This assay, however, does not exclude indirect 301 
binding, e.g. via C3-fragments, which may explain the background binding of FH to the 302 
gelatin-coated control well. 303 
The interaction of FHR-1 with CRP was also studied by ELISA. Previously, CRP was 304 
shown to bind to several of its ligands in a pH-dependent manner, showing increased binding 305 
at slightly acidic pH, which may be observed at inflammatory sites (44). We used serum from 306 
a sepsis patient to analyze the binding of native CRP to immobilized FHR-1 at various pH. No 307 
CRP binding was detected at pH 7.4, whereas significant binding of CRP to FHR-1 was 308 
detected at pH 6.5 and pH 5.5. Similar binding was observed in the case of the FHR-5 protein, 309 
whereas no CRP binding to FH was observed under these conditions (Fig. 2B). To analyze 310 
direct protein interactions, these experiments were also performed using recombinant native 311 
pCRP and yielded similar results (Fig. 2C). 312 
We set out to clarify which form of CRP interacts with FHR-1. Binding of the native 313 
pentameric pCRP to all human FHR proteins was measured by ELISA in Ca2+-containing 314 
buffer at physiological pH. To this end, FH family proteins were immobilized in microtiter 315 
plate wells and binding of pCRP added in increasing concentrations up to 50 µg/ml (~435 316 
nM) was measured using polyclonal CRP-specific antibody. pCRP bound strongly to FHR-4, 317 
as expected (42), and much more weakly to FHR-3 (Fig. 3A). There was marginal binding to 318 
FHR-5 at the highest investigated pCRP concentration, whereas no pCRP binding to FH, 319 
FHR-1 and FHR-2 was observed at this pH. However, mCRP that was generated from pCRP 320 
by urea-chelation treatment, showed strong binding to FHR-1, FH and FHR-5 (Fig. 3B). 321 
 Previously, a mCRP binding site in CCPs 19-20 of FH was identified (24). Therefore, 322 
we studied whether the homologous CCPs 4-5 of FHR-1 also harbour a binding site for 323 
mCRP. To this end, the homologous C-terminal two domains of all five FHR proteins were 324 
studied for mCRP binding in ELISA. CCPs 4-5 of FHR-1 bound mCRP similar to CCPs 19-325 
20 of FH. None of the other homologous FHR C-terminal domains bound mCRP (Fig. 3B). 326 
 The two FHR-1 allelic variants were also analyzed for mCRP binding using FHR-1*A 327 
and FHR-1*B purified from plasma of homozygous carriers of each allele. The two variants 328 
bound mCRP equally well (Fig. 3C). 329 
 Binding of FHR-1 to surface-bound CRP was measured by ELISA. To this end, CRP 330 
was immobilized in microplate wells, resulting in the generation of mCRP (42), and serial 331 
dilutions of FHR-1, FH and FHR-5 were added. Binding of the three FH family proteins was 332 
detected with polyclonal anti-FH. Whilst the antibody shows less reactivity with FHR-5, due 333 
to the lower sequence identity to FH, than between FH and FHR-1, a stronger signal for FHR-334 
5 was obtained compared with that for FHR-1 (Fig. 3D). 335 
 336 
Confirmation of the mCRP binding site in FHR-1 337 
To further confirm the C-terminal mCRP binding site in FHR-1, the mAb C18 was used, 338 
which binds in CCP20 of FH and CCP5 of FHR-1 (40, 41). This mAb strongly inhibited 339 
mCRP binding to FHR-1 (~70% inhibition under the experimental conditions), whereas a 340 
control mAb that binds in the middle portion of FH did not interfere with mCRP binding (Fig. 341 
4A). 342 
 Because most FH autoantibodies that are associated with the autoimmune form of 343 
aHUS also bind within these FH domains and cross-react with FHR-1 (20, 40, 45), we tested 344 
three IgG preparations isolated from FH autoantibody positive aHUS patients. Of the three 345 
IgGs, two inhibited mCRP binding to FHR-1 (Fig. 4B), by ~70% and ~50%, respectively, 346 
while all three inhibited C3b binding (not shown). 347 
 Some of the aHUS-associated C-terminal FH mutations were shown to impair the 348 
binding of FH to CRP indicating the role of FH residues 1183, 1197, 1210 and 1215 in CRP 349 
binding (24). Because the same FHR-1 and FH domains were shown to include a binding site 350 
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for the CRP homolog pentraxin PTX3 (22, 23, 35), we analyzed the binding of PTX3 to 14 351 
different recombinant FH CCPs 19-20 fragments containing single amino acid substitutions. 352 
This approach, similar to results obtained previously using peptide array (23), identified 353 
residues 1182-1186 and 1203-1215 relevant in PTX3 binding, thus at least partially 354 
overlapping with the mCRP binding site (Fig. 4C). In line with this, the two pentraxins mCRP 355 
and PTX3 partially competed for FHR-1 binding, mCRP caused a ~40% reduction in PTX3 356 
binding at the tested highest concentration (Fig. 4D). The pentraxin binding sites, as well as 357 
the binding sites for C3b and sialic acid, are shown on a surface representation of the FH19-358 
20 structure (Fig. 4E). 359 
 360 
FHR-1 competes with FH for mCRP binding 361 
Recent evidence supports a role for some of the FHR proteins as competitive inhibitors of FH 362 
on certain ligands, such as C3b, pentraxins and the extracellular matrix (10, 21, 35). 363 
Therefore, we investigated whether FHR-1 and FH compete for CRP binding due to the 364 
homologous mCRP binding sites in FHR-1 CCPs 4-5 and FH CCPs 19-20. To this end, the C-365 
terminal FH fragment CCPs 15-20 was immobilized on microplate wells, and binding of 366 
mCRP to these domains in the presence of FHR-1 was measured. FHR-1 at 1 µM 367 
concentration significantly inhibited mCRP binding to FH CCPs 15-20; FHR-1 caused a 368 
~25% inhibition in binding as compared to the control protein HSA (Fig. 5A). FHR-1 did not 369 
compete with FHL-1 for mCRP (not shown). 370 
To assess the functional effect of this competition, FHR-1 was added to normal human 371 
serum (Fig. 5B) and FH-depleted serum (Fig. 5C), and incubated on CRP-coated wells. Even 372 
when exogenous FHR-1 was added at 2 µM concentration to 12.5% human serum, no 373 
significant increase in C3 deposition was detected. By contrast, FHR-5 at 300 nM 374 
significantly increased C3 deposition in both sera (Fig. 5B and C). 375 
 376 
FHR-1 has no significant complement regulating activity for C3b and the terminal 377 
pathway 378 
Because previous reports are controversial regarding FHR-1 as a complement inhibitor (12, 379 
20, 21), we set out to clarify this issue. First the ability of FHR-1 to regulate the alternative 380 
pathway C3 convertase was measured. FHR-1 up to 1 µM did not inhibit the binding of FB to 381 
C3b and the formation and activity of the C3bBb convertase (Fig. 6A and 6B). FHR-1 also 382 
did not interfere with the ability of FH to regulate the C3 convertase even if FHR-1 was added 383 
in 16-fold molar excess to FH, whereas FHR-5 at 10-fold molar excess to FH resulted in 384 
~50% inhibition of FH decay accelerating activity (Fig. 6C). 385 
 The capacity of FHR-1 to inhibit the terminal pathway was assessed in serum. 386 
Activation of the alternative pathway was induced by addition of zymosan and the formation 387 
of soluble C5b-9 complexes was measured by ELISA. In this assay, 1 µM (and even 2 µM) 388 
FHR-1 did not inhibit zymosan-induced C5b-9 generation whereas addition of 1 µM FH 389 
resulted in ~40% inhibition of C5b-9 formation (Fig. 7). 390 
 391 
The FHR-1:mCRP interaction allows for enhanced C1q binding and classical pathway 392 
activation 393 
To analyze if FHR-1 bound mCRP can still bind C1q, FHR-1 was immobilized in microplate 394 
wells and incubated with or without mCRP. Then serial dilutions of purified C1q were added 395 
and C1q binding was measured. C1q bound to FHR-1 in a dose-dependent manner and 396 
mCRP, particularly at lower C1q concentrations, significantly enhanced C1q binding (Fig. 397 
8A). C1q showed background binding to gelatin, used as control, and mCRP did not affect 398 
this interaction. Similarly, mCRP bound to FHR-1 was able to bind the purified C1 complex 399 
(Fig. 8B). 400 
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 We also assessed if this interaction supports classical pathway activation. FHR-1 was 401 
immobilized in microplate wells and preincubated or not with mCRP before incubating with 402 
1% normal human serum. The bound mCRP on immobilized FHR-1 was able to activate the 403 
classical pathway and caused significantly enhanced C4 deposition (Fig. 8C). We also 404 
measured classical pathway activation on cell-derived ECM. ARPE-19 cells were cultured in 405 
96-well plates and the ECM produced by these retinal pigmented epithelial cells was used in 406 
an ELISA setting. The washed, cell-free ECM was incubated with recombinant FHR-1 and 407 
mCRP as above, followed by addition of 1% human serum. On this ECM surface, mCRP 408 
when bound to FHR-1 significantly increased classical pathway activation measured as 409 
increased deposition of C4-fragments (Fig. 8D). 410 
 411 
FHR-1 supports formation of the C3bBb convertase via C3b binding 412 
FHRs lack the C3b and C3 convertase regulating activities of FH, but it was demonstrated 413 
that C3b binding to FHR-4 and FHR-5 can allow the formation of a fully active C3bBb 414 
convertase (35, 36). We therefore tested whether FHR-1 shares this ability. To this end, FHR-415 
1 was immobilized on microplate wells and formation of C3bBb in vitro was measured by 416 
sequential incubation with C3b and FB plus FD plus properdin. A significant amount of 417 
C3bBb was formed on FHR-1 in this assay but this was significantly less than that formed on 418 
C3b (Fig. 9A). The less amount of C3bBb formed on FHR-1 in this particular assay is 419 
explained by the less C3b bound to FHR-1 compared to the amount of C3b bound to the plate 420 
surface when directly immobilizing C3b. The FHR-1 bound convertase was active as 421 
demonstrated by the conversion of C3 to C3a (Fig. 9B), suggesting that similar to FHR-4 and 422 
FHR-5, FHR-1 is able to support activation of the alternative pathway. FB and properdin did 423 
not directly bind to FHR-1 (Supplemental Fig. 1). 424 
 We also tested whether complement activation on FHR-1 occurs in serum. Wells 425 
coated with FHR-1, and as positive and negative controls, respectively, with FHR-4B and 426 
HSA, were incubated with normal human serum in buffer containing Mg2+/EGTA to allow 427 
activation of only the alternative pathway. The binding of C3 fragments, FB and properdin to 428 
FHR-1 was detected, similar to FHR-4B, indicating the formation of the properdin-stabilized 429 
C3bBb alternative pathway convertase and complement activation in serum by FHR-1 (Fig. 430 
9C). 431 
 To test if mCRP has an influence on this ability of FHR-1 to activate complement, e.g. 432 
due to partly overlapping binding site for C3b (see Fig. 4E), we first measured if mCRP-433 
bound FHR-1 can still bind C3b. To this end, mCRP was immobilized in microplate wells and 434 
incubated with FHR-1, followed by the addition of C3b. This experiment showed that mCRP-435 
bound FHR-1 was still able to bind C3b, but required higher C3b concentration than without 436 
mCRP (Fig. 10A, Fig. S1). In line with this, when ARPE-19 cell-derived ECM was used, 437 
mCRP on the ECM was able to bind FHR-1 and such bound FHR-1 could serve as a platform 438 
for the assembly of the C3bBb convertase (Fig. 10B). 439 
 Previously, FHR-1 was shown to bind to necrotic HUVEC (46). Therefore, HUVEC 440 
were necrotized by heat treatment, and the necrotic cells were incubated with FHR-1 alone or 441 
with mCRP followed by FHR-1, and exposed to 5% human serum. FHR-1 increased 442 
complement activation, as measured by the presence of FB as part of the alternative pathway 443 
convertase on the cell surface, which was enhanced by preincubation with mCRP (Fig. 10C). 444 
These data indicate that FHR-1 can enhance complement activation in cooperation with 445 
mCRP on certain non-cellular and cellular surfaces. 446 
447 
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Discussion 448 
Recent studies have changed our understanding of the functions of the FHR proteins (1), 449 
demonstrating a role of these proteins, including FHR-1, in enhancing complement activation, 450 
mainly via competition with the alternative pathway inhibitor FH. Although it is well 451 
established that FHR-1 does not compete with FH on host cell surfaces under normal healthy 452 
conditions (reviewed in (1)), very little is known about the FHR-1 ligands and the conditions 453 
under which competition between FHR-1 and FH may occur. Similarly, the possibility that 454 
FHR-1 has additional functions has not been sufficiently explored. CRP-complement cross-455 
talk is implicated in the opsonophagocytic removal of dying cells and cellular debris (24, 47, 456 
48). Because CRP-FH interaction was described to down-regulate inflammation (24, 31) and 457 
enhance the silent phagocytosis of apoptotic particles (24), and particularly impaired 458 
interaction between CRP and FH was suggested to be involved in the pathogenesis of AMD 459 
(32, 33), we investigated the ability of FHR-1 to bind CRP. 460 
In this study we show that FHR-1, in its native form from serum and also in 461 
recombinant form, binds to CRP. As in the case of several of its ligand interactions, CRP 462 
binds to FHR-1 in a pH-dependent manner with increased binding at slightly acidic pH, a 463 
condition characteristic to inflammatory environments (Fig. 2). A more detailed analysis 464 
revealed that it is not the native, pentameric form of CRP which binds FHR-1 but the 465 
modified mCRP form, which is sometimes termed monomeric or denatured CRP, although 466 
this does not necessarily mean formation of CRP monomers or the requirement of harsh 467 
conditions. mCRP may be generated at acidic pH, increased temperature, in low-Ca2+ 468 
conditions or by binding to membranes and surfaces including plastic ones, in vitro (26, 27, 469 
30, 42, 44, 49, 50). Remarkably, while CRP has been shown to bind FH also at lower pH (44), 470 
in our assays CRP binding to FHR-1 and FHR-5 could readily be detected under conditions 471 
when FH binding was not observed (Fig. 2). 472 
The CRP binding site in FHR-1 is located in the C terminus of the protein (Fig. 3 and 473 
4). This is not unexpected since CCPs 4-5 of FHR-1 are homologous with CCPs 19-20 of FH, 474 
which were previously shown to contain a major CRP binding site (24, 51). The FHR-1*A 475 
isoform is associated with AMD (52). We found no difference between the two FHR-1 476 
isoforms in binding mCRP. The similar capacity of FHR-1*A and FHR-1*B to bind mCRP is 477 
likely explained by the fact that the CCPs 4-5 are identical in the two FHR-1 allelic variants. 478 
FHR-1 indeed competed with the C-terminal FH fragment FH15-20 (Fig. 5), but not 479 
with FHL-1, which contains another mCRP binding site in CCP7. In serum, however, FHR-1 480 
in contrast to FHR-5 caused only slightly but not significantly increased C3 deposition on 481 
CRP via competitive inhibition of FH (Fig. 5), likely due to its weaker binding to CRP 482 
compared with FH and FHR-5 (Fig. 3D). In addition, FH contains three CRP binding sites 483 
(24, 31, 51). For the FH:CRP interaction, an apparent KD value of 4.2 µM was determined; for 484 
the FH fragment CCPs 6-8 (Y402 variant) a KD value of 3.9 µM, and for CCPs 16-20 a KD 485 
value of 15.3 µM (51). Thus, in FHR-1 the weaker CRP binding site of FH is conserved. 486 
Therefore, given the serum concentrations of FH and FHR-1 it is unlikely that under normal 487 
circumstances, even at enhanced CRP concentrations, functionally significant competition 488 
between the two FH-family proteins occurs that translates into enhanced complement 489 
activation. It cannot be excluded, however, that under certain conditions, such as local 490 
acidification, increase in FHR-1 concentration, or increased homo- and hetero-491 
oligomerization between FHR-1 and FHR-5, complement deregulation may also take place on 492 
CRP. Such scenarios are feasible, because transcriptome analysis showed that the CFHR1 493 
gene is highly expressed in human retinal pigment epithelium (53), altered FHR-1 protein 494 
levels were described under inflammatory and disease conditions (54, 55), and mutation in 495 
CFHR1 may result in higher order FHR-1 homo-oligomer formation with increased capacity 496 
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to out-compete FH (10). In addition, normal FH serum levels show significant variability in 497 
individuals, with reported ranges of 116-562 µg/ml (56) and 124.4-402 µg/ml (57). 498 
The binding site in FHR-1 CCPs 4-5 of CRP apparently overlaps with that of the 499 
related pentraxin PTX3 (Fig. 4) (35). This binding site was confirmed using the mAb C18, 500 
which binds in FHR-1 CCP5 and inhibits both mCRP and PTX3 binding to FHR-1, and by 501 
analysis of recombinant mutant proteins; in addition, aHUS-associated FH autoantibodies 502 
may also impair these interactions (Fig. 4) (23, 24). In line with these results, we observed 503 
partial competition between mCRP and PTX3 for binding to FHR-1. During acute phase 504 
response, systemically strongly increased CRP levels may favour FHR-1 binding to CRP over 505 
PTX3, but when the amount of PTX3 is locally increased, PTX3 binding may prevail. Of 506 
note, PTX3 is expressed in human retinal pigment epithelial cells and is upregulated by IL-1β 507 
and TNF-α (58). 508 
Thus, it seems that, due to its weaker binding to CRP and PTX3 compared with FH, 509 
normally FHR-1 does not significantly deregulate complement activation via competition 510 
with FH on these ligands. Deregulation may, however, occur when avidity of FH to these 511 
ligands is decreased (e.g., due to FH mutations or FH polymorphisms), or if the avidity of 512 
FHR-1 is increased (e.g., due to mutation influencing the oligomeric state of the protein, or 513 
when high levels of ligand deposition enable divalent binding by FHR-1). It is possible that 514 
there is competition between FHR-1 and FH on other modified or newly exposed ligands, 515 
such as malondialdehyde epitopes and proteins of the extracellular matrix (currently under 516 
investigation). For example, FHR-1 could likely pass through the Bruch’s membrane and may 517 
compete with FHL-1; even though FH has higher concentration than FHL-1, due to its size it 518 
cannot pass the pores in the fenestrated endothelium in the Bruch’s membrane very efficiently 519 
(59). Under these conditions, interaction of FHR-1 with the extracellular matrix and CRP may 520 
enhance complement activation (Fig. 8, Fig. 10). The inverse association of the CFHR1 gene 521 
deletion with AMD could partly be explained by our data: in AMD, local inflammation and 522 
pH change may favour FHR-1:CRP interaction, but the lack of FHR-1 would leave more 523 
room for the anti-inflammatory complement regulators FH and FHL-1. 524 
Because of the debated complement inhibiting function of FHR-1, we examined its 525 
role in alternative pathway C3 convertase regulation and terminal pathway inhibition. In our 526 
assays, FHR-1 did not prevent assembly of the alternative pathway C3 convertase, did not 527 
accelerate the decay of the convertase, and did not competitively inhibit the convertase decay 528 
accelarating activity of FH (Fig. 6). Both FH and FHR-1 bind to C3b/C3d via their C termini 529 
and a recent study confirmed that in FHR-1 the C-terminal C3b binding site of FH is 530 
essentially conserved (60). Previously both weaker (a KD value of 6.4 µM for the interaction 531 
of CCPs 1-3 of FHR-1 with C3b versus 2.6 µM for CCPs 18-20 of FH with C3b) (12, 61) and 532 
similarly strong (a KD value of ~4 µM for the interaction of FHR-1-like mutant FH19-20 with 533 
C3b versus ~6 µM for FH19-20 (19, 62, 63) binding of FHR-1 to C3b as compared with FH 534 
were described; in our convertase assay no significant competition was observed. FHR-1 535 
could also not inhibit soluble C5b-9 generation in our zymosan-induced complement 536 
activation assay (Fig. 7). Likewise, in a recent study we found no inhibition of serum C5b-9 537 
generation caused by liposomes or cremophore EL micelles (64). Thus, our results and the 538 
majority of literature data (10, 21, 64) do not support the previously suggested terminal 539 
pathway inhibiting function of FHR-1.  540 
Because C1q is one of the main complement ligands of CRP that can initiate classical 541 
pathway activation, we examined the influence of FHR-1 on this interaction. We found that 542 
FHR-1 bound mCRP could still bind C1q; the observed C1q binding to FHR-1 was 543 
significantly enhanced by mCRP (Fig. 8). C1q binding also occurred in the context of C1. 544 
Moreover, FHR-1-bound mCRP supported classical pathway activation, also on extracellular 545 
matrix produced in vitro by retinal pigmented epithelial cells (Fig. 8). 546 
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Importantly, FHR-1 by binding C3b allowed for the assembly of a functionally fully 547 
active alternative pathway C3 convertase and supported alternative pathway activation (Fig. 548 
9). When FHR-1 was bound on mCRP, more C3b was required to form the C3bBb convertase 549 
on FHR-1 (Fig. 10A and B), likely due to the partially overlapping binding sites (Fig. 4E). 550 
This interaction, however, also supported alternative pathway activation on the surface of 551 
necrotic cells exposed to serum, indicating that mCRP and FHR-1 may cooperate in 552 
enhancing opsonization (Fig. 10C). Thus, we identify a new function of FHR-1 in the 553 
activation of complement, a role in striking contrast to that of the inhibitor FH, and similar to 554 
that described for FHR-4 and FHR-5 (35, 36). 555 
In summary, CRP is identified and characterized as a novel ligand of FHR-1. Our 556 
results add to the growing body of evidence that, contrary to previous claim, FHR-1 is not an 557 
inhibitor of the terminal complement pathway. Instead, FHR-1 is shown to allow alternative 558 
pathway C3 convertase formation and alternative pathway activation. The FHR-1:mCRP 559 
interactions can enhance both classical and alternative pathway activation. Thus, FHR-1 560 
promotes rather than inhibits complement activation. 561 
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Figure legends 822 
 823 
Fig. 1. Schematic drawing of FH and the FHR-1 isoforms. 824 
FH is built up of 20 CCP domains, of which CCPs 1-4 mediate complement regulatory 825 
activity and CCPs 7, and 19-20 mediate surface recognition by FH. The FHR-1 domains are 826 
shown aligned with the corresponding most related FH domains. The numbers above the 827 
domains indicate the percentage of amino acid sequence identity between the homologous 828 
domains. CCP3 of the FHR-1*B variant is identical with CCP18 of FH whereas CCP3 of 829 
FHR-1*A differs in three amino acid from CCP18 of FH. In addition, α and β glycoforms are 830 
differentiated based on glycosylation pattern (not shown). 831 
 832 
Fig. 2. Binding of FHR-1 to CRP. 833 
(A) Microplate wells were coated with gelatin and CRP, and after blocking, incubated with 834 
50% normal human serum or PBS. Bound proteins were eluted with SDS-sample buffer, 835 
subjected to 10% SDS-PAGE and western blotting. The blot was developed using polyclonal 836 
anti-FH. Representative of three experiments. 837 
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(B) Microplate wells were coated with purified FH, recombinant FHR-1 and FHR-5 proteins, 838 
and HSA as negative control. Human serum with CRP level of 161 µg/ml from a sepsis 839 
patient was added at different pH values. Bound CRP was detected with polyclonal anti-CRP. 840 
Data are means ± SD derived from four independent experiments. *p < 0.05, **p < 0.01, one-841 
way ANOVA. 842 
(C) The experiment described in (B) was also performed using 5 µg/ml (~43 nM) 843 
recombinant CRP. Data are means ± SD derived from three independent experiments. *p < 844 
0.05, **p < 0.01, one-way ANOVA. 845 
 846 
Fig. 3. Comparison of the binding of pCRP and mCRP to the FHR proteins. 847 
(A) Binding of the native pentameric CRP to recombinant FHR proteins and FH by ELISA. 848 
The FH family proteins and human serum albumin (HSA), used as negative control, were 849 
immobilized in equimolar concentrations (200 nM) in microplate wells, then incubated with 850 
recombinant CRP. CRP binding was determined using a polyclonal anti-CRP antibody. Data 851 
are means ± SD derived from three independent experiments. *p < 0.05, ***p < 0.001, two-852 
way ANOVA. 853 
(B) Binding of the monomeric form of CRP (mCRP), generated by urea/EDTA chelation, was 854 
investigated by ELISA. FHR proteins, FH and the homologous C-terminal two domains of all 855 
five FHR proteins were immobilized, and the binding of 10 µg/ml mCRP was detected using 856 
a polyclonal anti-CRP antibody. Data are means ± SD derived from three independent 857 
experiments. ***p < 0.001, one-way ANOVA. 858 
(C) Binding of increasing concentrations of mCRP to immobilized FHR-1*A and FHR-1*B 859 
isoforms was measured as in (B). No difference of mCRP binding to the two allelic isoforms 860 
of FHR-1 was detected by ELISA. 861 
(D) Binding of increasing concentrations of FH, FHR-5 and FHR-1 to immobilized CRP was 862 
detected with polyclonal anti-FH antibody. HSA was used as control protein. Data are means 863 
± SEM derived from three independent experiments. The binding of each of FH, FHR-5 and 864 
FHR-1 was significantly different from that of HSA. *p < 0.05, **p < 0.01, and ***p < 0.001, 865 
two-way ANOVA. 866 
 867 
Fig. 4. Analysis of the mCRP binding site in FHR-1. 868 
(A) To confirm the binding site in FHR-1, mCRP binding was measured in the presence of a 869 
monoclonal antibody (C18) which is known to bind to the C-terminal of FH and FHR-1. As a 870 
control antibody, A255 was used which binds to the middle region of FH. Data are means ± 871 
SD derived from three independent experiments. ***p < 0.001, one-way ANOVA. 872 
(B) The binding of mCRP to immobilized FHR-1 was measured in the presence of IgG 873 
fractions isolated from healthy individuals (H1-H3) or from aHUS patients with FH 874 
autoantibodies (P1-P3). Data are normalized to mCRP binding in the absence of IgG and 875 
represent means ± SD derived from three independent experiments. ***p < 0.001, one-way 876 
ANOVA. 877 
(C) To identify residues relevant in PTX3 binding, mutant FH 19-20 fragments were coated 878 
and after blocking and washing, 5 µg/ml PTX3 was added to the wells. Bound PTX3 was 879 
measured using a polyclonal anti-PTX3 antibody. Data are means ± SD derived from three 880 
independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001, one-way ANOVA. 881 
(D) Competition between mCRP and PTX3 for FHR-1. FHR-1 was coated and the binding of 882 
5 µg/ml PTX3 in the presence of mCRP was measured. Data are means ± SD derived from 883 
three independent experiments. *p < 0.05, one-way ANOVA. 884 
(E) The ligand binding sites (residues in black) were plotted on a FH19-20 surface 885 
representation (structure derived from Protein Data Bank, accession code 2G7I (43)) using 886 
PyMOL, based on the results shown in (C) for PTX3 and previous results for mCRP (24). The 887 
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main C3b and sialic acid interacting residues are indicated based on previous structural 888 
studies (15, 18, 19). 889 
 890 
Fig. 5. FHR-1 competes with the C terminus of FH for mCRP binding. 891 
(A) The C-terminal FH fragment FH 15-20 was immobilized in microplate wells, and binding 892 
of 5 µg/ml mCRP to these domains in the presence of 1 µM FHR-1 was measured using a 893 
polyclonal anti-CRP antibody. Data are means ± SD derived from three independent 894 
experiments. *p < 0.05, one-way ANOVA. 895 
(B) CRP was immobilized and normal human serum was added in the absence or presence of 896 
recombinant FHR-1 protein (2 µM). The amount of deposited C3 fragments, due to CRP 897 
induced complement activation, was measured with a polyclonal anti-C3 antibody. Data are 898 
means ± SD derived from four independent experiments. ***p < 0.001, one-way ANOVA. 899 
(C) The assay described above was also conducted using FH-depleted serum. Data are means 900 
± SD derived from three independent experiments. **p < 0.01, one-way ANOVA. 901 
 902 
Fig. 6. FHR-1 has no significant complement regulatory activity at the level of the 903 
alternative pathway C3 convertase. 904 
(A) The capacity of FHR-1 to inhibit the formation of the solid phase C3bBb alternative 905 
pathway C3 convertase was studied in this experiment. The convertase components FB, FD 906 
and properdin were added to coated C3b in the presence of FH (10 µg/ml), FHR-5 (10 µg/ml), 907 
FHR-1 (50 µg/ml) or BSA (50 µg/ml), and the amount of the assembled convertase was 908 
measured after incubation with a polyclonal anti-FB antibody. Data are means ± SD derived 909 
from three independent experiments. *p < 0.05, one-way ANOVA. 910 
(B) After the assembly of the convertase as described above, purified human C3 was added 911 
and the amount of the generated C3a was detected with an ELISA Kit. Data are means ± SD 912 
derived from three independent experiments. ***p < 0.001, one-way ANOVA. 913 
(C) To assess the effect of FHR-1 on the decay of the alternative pathway C3 convertase, pre-914 
assembled C3 convertase was incubated with 2.5 µg/ml FH, 10 µg/ml FHR-1, 10 µg/ml FHR-915 
5 or FH together with FHR-1 or FHR-5 of the same concentrations. The normalized data are 916 
means ± SD derived from three independent experiments. *p < 0.05, **p < 0.01, one-way 917 
ANOVA. 918 
 919 
Fig. 7. FHR-1 does not inhibit terminal pathway in vitro. 920 
The alternative pathway was activated in NHS by adding 20 µg/ml zymosan and the capacity 921 
of FHR-1 to inhibit the terminal pathway was measured by detecting the formation of soluble 922 
C5b-9 complexes by ELISA. FHR-1 up to 2 µM did not inhibit zymosan induced C5b-9 923 
generation. FH (1 µM) was used as control. Data are means ± SD derived from three 924 
independent experiments. *p < 0.05, one-way ANOVA. 925 
 926 
Fig. 8. FHR-1 bound mCRP binds C1q and allows for classical pathway activation. 927 
(A) FHR-1 was immobilized in microplate wells and incubated with or without 5 µg/ml 928 
mCRP. After washing, serial dilutions of purified C1q in the indicated concentrations were 929 
added and the C1q binding was measured with a polyclonal anti-C1q antibody. Gelatin was 930 
used as a negative control. Data are means ± SD derived from three independent experiments. 931 
The binding of C1q to FHR-1 was significantly different in the presence of mCRP compared 932 
with the binding in the absence of mCRP (p < 0.0001, two-way ANOVA).  933 
(B) Binding of 10 µg/ml purified C1 complex to wells coated with 4 µg/ml recombinant FHR-934 
1 and preincubated with 5 µg/ml mCRP as in (A) was measured using a polyclonal anti-C1q 935 
antibody. Wells coated with gelatin were used as a negative control. Data are means ± SD 936 
derived from three independent experiments. ***p < 0.001, one-way ANOVA. 937 
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(C) FHR-1 and gelatin were immobilized in microplate wells and preincubated or not with 5 938 
µg/ml mCRP. 1% normal human serum in DPBS containing Ca2+/Mg2+ (NHS) or NHS in 939 
DPBS containing 20 mM EDTA was added for 30 min at 37ºC, then C4-fragment deposition 940 
was detected using a polyclonal anti-C4 antibody. Data represent means ± SD from three 941 
independent experiments. **p < 0.01, one-way ANOVA. 942 
(D) ARPE-19 cells were cultured in 96-well plates for 7 days. After removal of the cells, the 943 
cell-derived ECM was incubated sequentially with FHR-1 and mCRP, then exposed to 1% 944 
normal human serum (NHS) or NHS/EDTA for 30 min at 37ºC. C4-fragment deposition was 945 
detected using a polyclonal anti-C4 antibody. Data are means ± SD from three independent 946 
experiments. **p < 0.01, one-way ANOVA. 947 
 948 
Fig. 9. FHR-1 supports rather than inhibits complement activation. 949 
(A) Assembly of the C3bBb convertase on FHR-1. Recombinant FHR-1, BSA as negative 950 
control and C3b as positive control were immobilized in microplate wells, followed by 951 
incubation with 10 µg/ml C3b. The alternative pathway C3 convertase was built up by adding 952 
purified FB, factor D and FP for 30 min at 37°C. The convertase was detected with polyclonal 953 
anti-FB antibody. Data are means ± SD derived from four independent experiments. **p < 954 
0.01, ***p < 0.001, one-way ANOVA. 955 
(B) Activity of the FHR-1-bound convertase was measured by adding 10 µg/ml C3 to the 956 
wells for 1 h at 37°C. C3a generation was measured by Quidel’s C3a ELISA kit. Data are 957 
means ± SD derived from three independent experiments. **p < 0.01, one-way ANOVA. 958 
(C) FHR-1 was immobilized on microplate wells and incubated with 10% normal human 959 
serum in 5 mM Mg2+-EGTA buffer to allow only alternative pathway activation. Deposition 960 
of C3b, factor B (FB) and properdin (FP) was detected using the corresponding antibodies. 961 
FHR-4B was used as positive control and human serum albumin (HSA) was used as negative 962 
control. Data are means ± SD derived from three independent experiments. *p < 0.05, **p < 963 
0.01, ***p < 0.001, one-way ANOVA. 964 
 965 
Fig. 10. FHR-1 activates the alternative pathway when bound to mCRP on surfaces. 966 
(A) C3b can bind to mCRP-bound FHR-1. Microplate wells were coated with 5 µg/ml mCRP, 967 
then incubated without or with 5 and 50 µg/ml recombinant FHR-1. After washing, C3b was 968 
added in 20 µg/ml (grey bars) or 50 µg/ml (black bars) concentration. C3b binding was 969 
detected using a polyclonal anti-C3 antibody. Data are means ± SD derived from three 970 
independent experiments. The binding of C3b was significantly enhanced in the presence of 971 
50 µg/ml FHR-1 compared with wells without FHR-1 (*p < 0.05, **p < 0.01, one-way 972 
ANOVA). 973 
(B) Assembly of the alternative pathway C3 convertase C3bBb was measured on ECM 974 
produced by ARPE-19 cells in vitro, by incubating the washed, cell-free ECM with mCRP 975 
followed by FHR-1. After preincubating the ECM with 50 µg/ml C3b, the convertase was 976 
built up by adding purified FB, FD and FP for 30 min at 37°C. The convertase was detected 977 
with anti-FB antibody. Data are means ± SD derived from four independent experiments. *p < 978 
0.05, one-way ANOVA. 979 
(C) Necrotic HUVEC were generated by heat treatment. The washed necrotic cells were 980 
preincubated or not with 2.5 µg/ml mCRP, incubated with 25 µg/ml FHR-1, then exposed to 981 
5% normal human serum (NHS) for 30 min at 37°C. Activation of the alternative pathway 982 
was detected by flow cytometry using polyclonal anti-FB antibody and fluorescently labelled 983 
secondary antibody. Necrotic cells were identified by propidium iodide staining. 984 
Representative results out of three experiments are shown.  985 
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